Eli Lilly just lifted its 2026 sales outlook by $5.5bn, but can surging GLP-1 demand keep outrunning price pressure?
Eli Lilly raises 2026 revenue guidance to $91bn–$92bn as Mounjaro and Zepbound sales surge. Explore its earnings, pipeline and risks.